Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ACTIV-3b/TESICO: Remdesivir in COVID-19 with ARDS
NCT06729593Phase 3Completed
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Start
- Apr 2021
- Primary completion
- Aug 2022
- Modality
- Orthosteric Ligands, Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in coronavirus disease 2019 (COVID-19) comparing Remdesivir + SOC with Placebo + SOC (2 arms). Primary endpoint: Number of Participants With a 6-category Primary Ordinal Outcome (Recovery) at Day 90. Started Apr 2021; status: completed.
02
Drugs
remdesivir
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT06729593.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06729593.